An endothelin receptor antagonist, ambrisentan is a well-characterised drug and currently indicated for the treatment of some forms of Pulmonary Arterial Hypertension. Noorik is developing a micro-dose of ambrisentan, as there is some indication that ambrisentan, a potent endothelin receptor antagonist, may be more effective and result in fewer side effects at lower doses when compared to the higher doses currently available. Learn more...

COVID-19 is a disease resulting from the infection of the new SARS-CoV-2 coronavirus. This infection may result in a severe form of viral pneumonia characterised by low blood oxygen (hypoxia) and frequent progression to respiratory failure. Recently, there is an indication that patients with Severe COVID-19 develop lung blood flow abnormalities and similar to patients with Pulmonary Arterial Hypertension. Noorik is currently performing a clinical study in high-risk patients with Severe COVID-19 to determine whether ambrisentan as a pulmonary vasodilator, is safe and effective in improving low blood oxygen and preventing respiratory failure. Learn more...

Portal Hypertension is a common condition in patients advanced Liver Cirrhosis, the latter the end-stage complication from chronic liver diseases, such as NASH, hepatitis and Alcohol Liver Disease. About 40,000 people die of the complications of cirrhosis every year. Although liver transplantation is an option for some, a significant number of patients will die while waiting for a suitable organ. Direct complications of Portal Hypertension account for the majorityof the morbidity and mortality of patients with advanced Liver Cirrhosis. Learn more...